U.S. and Israel Launch Strikes on Iran
The U.S. and Israeli forces have launched major strikes against Iran, with explosions reported in Tehran. President Trump announced “major combat operations” are underway and called on Iranian citizens to “take over your government.” The escalation could disrupt international research collaborations and biotech supply chains.
This escalation follows a brief but intense war in June 2025, during which the U.S. and Israel also struck Iranian nuclear facilities. Despite several rounds of indirect talks since then, tensions have remained high over Iran's nuclear program and its support for regional proxy forces. Iran's biotechnology sector is a point of national pride and a key part of its strategy for economic self-sufficiency. The country ranks 13th globally in biotechnology publications and produces approximately 95% of its own medicines, with a growing focus on advanced biopharmaceuticals. Leading Iranian biotech firms like CinnaGen and AryoGen Pharmed produce complex medicines, including monoclonal antibodies and recombinant proteins. Iran exports over $200 million in biotech drugs to at least 17 countries, making its research and manufacturing hubs potential, if unintended, targets. The conflict immediately threatens global shipping through the Strait of Hormuz, a chokepoint for a vast amount of trade. This disruption drives up fuel and insurance costs, which in turn increases the price of raw materials essential for the life sciences, including active pharmaceutical ingredients (APIs) shipped from Asia. The instability also impacts the building blocks of biotech research. For example, plastics used in single-use lab systems, packaging, and other essential supplies are directly affected by freight hikes and shipping delays caused by regional conflict. Beyond physical goods, geopolitical tensions create "scientific protectionism." This can lead to restrictions on international research collaborations, barriers to sharing genomic or clinical data, and the freezing of academic partnerships, slowing down the pace of global scientific discovery. For those entering the life sciences, this volatility is reshaping career paths. Companies are now focused on supply chain resilience, leading to more "onshoring" of manufacturing and an increased demand for computational biologists and data scientists who can model and mitigate these geopolitical risks.
